Search research articles
Contact Us
Filters
Showing results (151-160 of 466) with videos related to
Page
of 47
Sort By:
The Journal of Antimicrobial Chemotherapy
|
July 31, 2020
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
International Journal of Antimicrobial Agents
|
November 19, 2023
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections
Pier Giorgio Cojutti, Milo Gatti, Nieko Punt, et al.
Infectious Diseases (London, England)
|
September 21, 2020
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
AIDS Research and Human Retroviruses
|
October 31, 2020
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir
Leonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Infectious Disease Reports
|
February 24, 2022
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
Pier Giorgio Cojutti, Giacomo Fornaro, Milo Gatti, et al.
The Journal of Antimicrobial Chemotherapy
|
December 13, 2018
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Health Care Management Review
|
May 17, 2024
Embracing tensions throughout crises: The case of an Italian university hospital during the COVID-19 pandemic
Massimo Bergami, Ludovico Bullini Orlandi, Paola Giuri, et al.
HIV Clinical Trials
|
May 18, 2012
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors
Leonardo Calza, Filippo Trapani, Michele Bartoletti, et al.
Journal of Global Antimicrobial Resistance
|
March 31, 2019
Clinical experience with dalbavancin for the treatment of deep sternal wound infection
Michele Bartoletti, Elisa Mikus, Renato Pascale, et al.
Infectious Diseases (London, England)
|
April 16, 2015
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients
Leonardo Calza, Ilaria Danese, Vincenzo Colangeli, et al.
Page
of 47
Search research articles
Search
Showing results (151-160 of 466) with videos related to
Sort By:
Page
of 47
The Journal of Antimicrobial Chemotherapy
|
July 31, 2020
Simplification to dual therapy containing lamivudine and raltegravir or dolutegravir in HIV-infected patients on virologically suppressive antiretroviral therapy
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
International Journal of Antimicrobial Agents
|
November 19, 2023
Implementation and validation of a Bayesian method for accurately forecasting duration of optimal pharmacodynamic target attainment with dalbavancin during long-term use for subacute and chronic staphylococcal infections
Pier Giorgio Cojutti, Milo Gatti, Nieko Punt, et al.
Infectious Diseases (London, England)
|
September 21, 2020
Rosuvastatin decreases serum inflammatory markers and slows atherosclerosis progression rate in treated HIV-infected patients with metabolic syndrome
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
AIDS Research and Human Retroviruses
|
October 31, 2020
Short Communication: No Significant Changes in Weight and Body Fat Mass in Suppressed HIV-Infected Patients Switched to Dual Combination Lamivudine Plus Dolutegravir or Raltegravir
Leonardo Calza, Marco Borderi, Vincenzo Colangeli, et al.
Infectious Disease Reports
|
February 24, 2022
Successful Treatment of Bacteremia and Ventilator-Associated Pneumonia Caused by KPC/OXA-48-like <i>Klebsiella pneumoniae</i> Co-Producer with a Continuous Infusion of High-Dose Meropenem Plus Fosfomycin Guided by Real-Time Therapeutic Drug Monitoring
Pier Giorgio Cojutti, Giacomo Fornaro, Milo Gatti, et al.
The Journal of Antimicrobial Chemotherapy
|
December 13, 2018
Improvement in insulin sensitivity and serum leptin concentration after the switch from a ritonavir-boosted PI to raltegravir or dolutegravir in non-diabetic HIV-infected patients
Leonardo Calza, Vincenzo Colangeli, Marco Borderi, et al.
Health Care Management Review
|
May 17, 2024
Embracing tensions throughout crises: The case of an Italian university hospital during the COVID-19 pandemic
Massimo Bergami, Ludovico Bullini Orlandi, Paola Giuri, et al.
HIV Clinical Trials
|
May 18, 2012
Statin therapy decreases serum levels of high-sensitivity C-reactive protein and tumor necrosis factor-α in HIV-infected patients treated with ritonavir-boosted protease inhibitors
Leonardo Calza, Filippo Trapani, Michele Bartoletti, et al.
Journal of Global Antimicrobial Resistance
|
March 31, 2019
Clinical experience with dalbavancin for the treatment of deep sternal wound infection
Michele Bartoletti, Elisa Mikus, Renato Pascale, et al.
Infectious Diseases (London, England)
|
April 16, 2015
Plasma concentrations of efavirenz, darunavir/ritonavir and raltegravir in HIV-HCV-coinfected patients without liver cirrhosis in comparison with HIV-monoinfected patients
Leonardo Calza, Ilaria Danese, Vincenzo Colangeli, et al.
Page
of 47